Oral delivery of protein drugs is greatly limited by low hydrophobicity, an important determinant for intestinal epithelial permeation and bioavailability. Herein, surface properties of recombinant erythropoietin were investigated using the fluorescent dye bis-ANS to monitor relative hydrophobicity for correlation with permeabilities with Caco-2 cells. At various pHs, bis-ANS fluorescence intensity indicated different surface hydrophobicities of erythropoietin molecules. Erythropoietin incorporated in chitosan or chitosan-trimethylchitosan (CS-TMC) nanoparticles prepared by polyelectrolyte complexation and ionotropic gelation with tripolyphosphate also showed different surface hydrophobicities. Chitosan nanoparticles with erythropoietin provided the most hydrophobic surface, followed by free erythropoietin (in water) and that loaded into CS-TMC nanoparticles. Chitosan nanoparticles were more effective than CS-TMC nanoparticles for permeation of erythropoietin across Caco-2 cell monolayers; the lowest permeability was shown by erythropoietin itself. Thus, hydrophilic protein molecules complexed with polyelectrolytes can provide more hydrophobic surfaces that enhance transepithelial permeability. This bis-ANS method also provides valuable information for the design of polyelectrolyte nanoparticules for oral delivery of protein drugs.
2. J. Wang, V. Yadav, A. L. Smart, S. Tajiri and A. W. Basit, Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs, Mol. Pharm. 12 (2015) 966–973; http://doi.org/10.1021/mp500809f
5. D. Vllasaliu, R. Exposito-Harris, A. Heras, L. Casettari, M. Garnett, L. Illum and S. Stolnik, Tight junction modulation by chitosan nanoparticles: Comparison with chitosan solution, Int. J. Pharm. 400 (2010) 183–193; http://doi.org/10.1016/j.ijpharm.2010.08.020
6. G. Camenisch, J. Alsenz, H. V. Waterbeemd and G. Folkers, Estimation of permeability by passive diffusion through Caco-cell monolayers using the drugs’ lipophilicity and molecular weight, Eur. J. Pharm. Sci.6 (1998) 317–324; http://doi.org/10.1016/S0928-0987(97)10019-7
7. B. F. Choonara, Y. E. Choonara, P. Kumar, D. Bijukumar, L. C. du Toit and V. Pillay, A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules, Biotechnol. Adv.32 (2014) 1269–1282; http://doi.org/10.1016/j.biotechadv.2014.07.006
8. T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J. X. Xiao and T. Kissel, Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50 (2000) 147–160; http://doi.org/10.1016/S0939-6411(00)00084-9
10. J. Mirtič, J. Ilaš and J. Kristl, Influence of different classes of crosslinkers on alginate polyelectrolyte nanoparticle formation, thermodynamics and characteristics, Carbohydrate polymers181 (2018) 93–102; http://doi.org/10.1016/j.carbpol.2017.10.040
12. L. Yin, J. Ding, C. He, L. Cui, C. Tang and C. Yin, Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery, Biomaterials30 (2009) 5691–5700; http://doi.org/10.1016/j.biomaterials.2009.06.055
13. Y. Li, X. Chen and N. Gu, Computational investigation of interaction between nanoparticles and membranes: Hydrophobic/hydrophilic effect, J. Phys. Chem. B.112 (2008) 16647–16653; http://doi.org/10.1021/jp8051906
14. J. Renukuntla, A. D. Vadlapudi, A. Patel, S. H. S. Boddu and A. K. Mitra, Approaches for enhancing oral bioavailability of peptides and proteins, Int. J. Pharm.447 (2013) 75–93; http://doi.org/10.1016/j.ijpharm.2013.02.030
21. I. Hubatsch, E. G. Ragnarsson and P. Artursson, Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers, Nat. Protoc. 2 (2009) 2111–2119; http://doi.org/10.1038/nprot.2007.303
22. K. Berginc, S. Žakelj, L. Levstik, D. Uršič and A. Kristl, Fluorescin transport properties across artificial lipid membranes, Caco-2 cell monolayers and rat jejunum, Eur. J. Pharm. Biopharm. 66 (2007) 281–285; http://doi.org/10.2016/j.ejpb.2006.10.023
23. M. Cegnar, B. Podobnik, S. Caserman, M. Homar and J. Kerc, EPO Compositions for Oral Administration, WO2015/032973 (A1), 12 Mar 2015.
24. M. Marušič, T. Zupančič, G. Hribar, R. Komel, G. Anderluh and S. Caserman, The Caco-2 cell culture model enables sensitive detection of enhanced protein permeability in the presence of N-decyl-ß-D-maltopyranoside, New Biotechnologies30 (2013) 507–515; http://doi.org/10.1016/j.nbt.2013.05.008
26. P. Maurel, Relevance of dielectric constant and solvent hydrophobicity to the organic solvent effect in enzymology, J. Biol. Chem.253 (1978) 1671–1683.
27. E. Y. Chi, S. Krishnan, T. W. Randolph and J. F. Carpenter, Physical stability of proteins in aqueous solution: mechanism and driving forces in non-native protein aggregation, Pharm. Res. 20 (2003) 1325–1336; http://doi.org/10.1023/A:1025771421906
28. A. M. M. Sadeghi, F. A. Dorkoosh, M. R. Avadi, M. Weinhold, A. Bayat, F. Delie, R. Gurny, B. Larijani, M. Rafiee-Tehrani and H. E. Junginger, Permeation enhancer effect of chitosan and chitosan derivatives: Comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells, Eur. J. Pharm. Biopharm. 70 (2008) 270–278; http://doi.org/10.1016/j.ejpb.2008.03.004.29
29. M. A. Mohammed, J. T. M. Syeda, K. M. Wasan and E. K. Wasan, An overview of chitosan nanoparticles and its application in non-parenteral drug delivery, Pharmaceutics9 (2017) E53; http://doi.org/10.3390/pharmaceutics9040053
30. I. Pereira de Sousa, C. Steiner, M. Schmutzler, M. D. Wilcox, G. J. Veldhuis, J. P. Pearson, C. W. Huck, W. Salvenmoser and A. Bernkop-Schnürch, Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles, Eur. J. Pharm. Biopharm. 97 (2015) 273–279; http://doi.org/10.1016/j.ejpb.2014.12.024